PL2734538T3 - Sposób odwracalnego barwienia komórki docelowej - Google Patents

Sposób odwracalnego barwienia komórki docelowej

Info

Publication number
PL2734538T3
PL2734538T3 PL12747985T PL12747985T PL2734538T3 PL 2734538 T3 PL2734538 T3 PL 2734538T3 PL 12747985 T PL12747985 T PL 12747985T PL 12747985 T PL12747985 T PL 12747985T PL 2734538 T3 PL2734538 T3 PL 2734538T3
Authority
PL
Poland
Prior art keywords
target cell
reversible staining
staining
reversible
target
Prior art date
Application number
PL12747985T
Other languages
English (en)
Other versions
PL2734538T5 (pl
Inventor
Thomas Schmidt
Christian STEMBERGER
Dirk H. Busch
Lothar Germeroth
Original Assignee
Iba Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46682800&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2734538(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Iba Gmbh filed Critical Iba Gmbh
Publication of PL2734538T3 publication Critical patent/PL2734538T3/pl
Publication of PL2734538T5 publication Critical patent/PL2734538T5/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00Sampling; Preparing specimens for investigation
    • G01N1/28Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/30Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/557Immunoassay; Biospecific binding assay; Materials therefor using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56972White blood cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00Labels used in chemical analysis of biological material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
PL12747985.5T 2011-07-18 2012-07-17 Sposób odwracalnego barwienia komórki docelowej PL2734538T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161508943P 2011-07-18 2011-07-18
PCT/EP2012/063969 WO2013011011A2 (en) 2011-07-18 2012-07-17 Method of reversibly staining a target cell
EP12747985.5A EP2734538B2 (en) 2011-07-18 2012-07-17 Method of reversibly staining a target cell

Publications (2)

Publication Number Publication Date
PL2734538T3 true PL2734538T3 (pl) 2018-10-31
PL2734538T5 PL2734538T5 (pl) 2025-11-12

Family

ID=46682800

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12747985.5T PL2734538T5 (pl) 2011-07-18 2012-07-17 Sposób odwracalnego barwienia komórki docelowej

Country Status (10)

Country Link
US (2) US9023604B2 (pl)
EP (2) EP2734538B2 (pl)
JP (2) JP6310388B2 (pl)
CN (2) CN107843730B (pl)
ES (1) ES2682750T5 (pl)
PL (1) PL2734538T5 (pl)
PT (1) PT2734538T (pl)
SI (1) SI2734538T2 (pl)
TR (1) TR201811128T4 (pl)
WO (1) WO2013011011A2 (pl)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201811128T4 (tr) * 2011-07-18 2018-08-27 Iba Gmbh Bir hedef hücrenin tersinir şekilde boyama yöntemi.
RU2746407C1 (ru) 2012-02-23 2021-04-13 Стейдж Селл Терапеутикс Гмбх Хроматографическое выделение клеток и других сложных биологических материалов
PT3524617T (pt) 2013-03-15 2023-07-12 Gladiator Biosciences Inc Domínios gla como agentes terapêuticos
BR112016024072B1 (pt) * 2014-04-16 2021-02-09 Juno Therapeutics Gmbh método in vitro de estimular uma população de células
RU2763795C2 (ru) 2014-04-23 2022-01-11 Джуно Терапьютикс, Инк. Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии
JP6661544B2 (ja) * 2014-04-24 2020-03-11 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 遺伝子改変したt細胞の自動生成法
CA2945414C (en) * 2014-04-30 2023-05-09 Iba Gmbh Method of isolating a target cell
EP3037820A1 (en) 2014-12-27 2016-06-29 Miltenyi Biotec GmbH Cell detection methods and reagents having a releasable labelling moiety
JP7297408B2 (ja) * 2015-02-06 2023-06-26 セル アイディーエックス, インコーポレイテッド 抗原をカップリングさせた免疫試薬
WO2016166568A1 (en) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
SG11201803330WA (en) * 2015-10-22 2018-05-30 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
US11248238B2 (en) 2015-10-22 2022-02-15 Juno Therapeutics Gmbh Methods, kits, agents and apparatuses for transduction
JP7194020B2 (ja) * 2015-10-22 2022-12-21 ジュノ セラピューティクス ゲーエムベーハー 細胞の培養方法ならびにそのためのキットおよび装置
CN109983133B (zh) * 2016-06-28 2023-09-08 慕尼黑工业大学 用于分析受体-配体Koff速率的可逆和不可逆细胞标记的组合
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
EP3336546B1 (en) 2016-12-13 2020-07-01 Miltenyi Biotec B.V. & Co. KG Reversible cell labelling with conjugates having two releasable binding sites
EP3336545A1 (en) * 2016-12-13 2018-06-20 Miltenyi Biotec GmbH Reversible labeling of antigens in biological specimens
WO2018112262A2 (en) 2016-12-16 2018-06-21 Diagnologix, Llc Buoyancy enabled separation method and system
MX2019008538A (es) 2017-01-20 2019-11-05 Juno Therapeutics Gmbh Conjugados de superficie celular y composiciones y métodos celulares relacionados.
JP7339160B2 (ja) 2017-04-27 2023-09-05 ジュノ セラピューティクス ゲーエムベーハー オリゴマー粒子試薬およびその使用方法
BR112020001719A2 (pt) 2017-07-29 2020-07-21 Juno Therapeutics Inc reagentes para expansão de células que expressam receptores recombinantes
AU2018313950A1 (en) 2017-08-09 2020-02-13 Juno Therapeutics, Inc. Methods for producing genetically engineered cell compositions and related compositions
SG11202001535RA (en) * 2017-09-05 2020-03-30 Gladiator Biosciences Inc Method of targeting exosomes
EP3704230B1 (en) 2017-11-01 2024-10-23 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
WO2019113557A1 (en) 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Process for producing a composition of engineered t cells
CN116148467A (zh) * 2017-12-12 2023-05-23 清华大学 检测翻译后修饰蛋白质与其配体间相互作用的成套试剂
CN113474450A (zh) 2018-08-09 2021-10-01 朱诺治疗学股份有限公司 产生工程化细胞的方法以及所述工程化细胞的组合物
WO2020048876A1 (en) 2018-09-03 2020-03-12 Technische Universitaet Muenchen A double peptide tag combining reversibility and flexible functionalization
MX2021002574A (es) 2018-09-11 2021-06-08 Juno Therapeutics Inc Metodos para el analisis por espectrometria de masas de composiciones de celulas modificadas.
EP3874024A1 (en) 2018-10-31 2021-09-08 Juno Therapeutics GmbH Methods for selection and stimulation of cells and apparatus for same
EP3877054B1 (en) 2018-11-06 2023-11-01 Juno Therapeutics, Inc. Process for producing genetically engineered t cells
JP7354285B2 (ja) 2019-04-23 2023-10-02 ミルテニー バイオテック ベー.フェー. ウント コー. カー・ゲー 蛍光輝度を増加させるためのリンカー及び酵素により遊離可能な蛍光部分を有する接合体での可逆的な細胞検出
CA3142108A1 (en) 2019-05-28 2020-12-03 Miltenyi Biotec B.V. & Co. KG Method for generation of genetically modified t cells
MX2021015125A (es) 2019-06-07 2022-04-06 Juno Therapeutics Inc Cultivo automatizado de celulas t.
EP4022637A2 (en) 2019-08-30 2022-07-06 Juno Therapeutics, Inc. Machine learning methods for classifying cells
US20220315894A1 (en) 2019-09-11 2022-10-06 Miltenyi Biotec B.V. & Co. KG Method for Transduction of T Cells in the Presence of Malignant Cells
WO2021084050A1 (en) 2019-10-30 2021-05-06 Juno Therapeutics Gmbh Cell selection and/or stimulation devices and methods of use
US20230090117A1 (en) 2020-01-28 2023-03-23 Juno Therapeutics, Inc. Methods for t cell transduction
IL295384B1 (en) 2020-02-12 2026-04-01 Juno Therapeutics Inc T-cell preparations with chimeric antigen receptor directed against CD19 and methods and uses thereof
IL295381B1 (en) 2020-02-12 2026-04-01 Juno Therapeutics Inc BCMA-directed chimeric T-cell antigen receptor compounds and methods and uses thereof
WO2021231661A2 (en) 2020-05-13 2021-11-18 Juno Therapeutics, Inc. Process for producing donor-batched cells expressing a recombinant receptor
WO2021261451A1 (ja) 2020-06-24 2021-12-30 旭化成メディカル株式会社 タンパク質含有溶液の評価方法
EP4204809A1 (en) 2020-08-27 2023-07-05 Miltenyi Biotec B.V. & Co. KG Releasable reagents for cell separation
CN112285083B (zh) * 2020-10-28 2022-01-07 上海睿钰生物科技有限公司 一种细胞杀伤效力的评价方法
US20250283037A1 (en) 2021-05-06 2025-09-11 Juno Therapeutics Gmbh Methods for stimulating and transducing t cells
WO2023147510A1 (en) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Chromatography arrays and related methods and kits
EP4227423A1 (en) 2022-02-09 2023-08-16 Technische Universität München Means and methods for identifying high affinity t-cells
CA3256271A1 (en) 2022-04-28 2023-11-02 Bio-Recell Ltd. TARGET CELL SEPARATION PROCESS
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
EP4532695A1 (en) 2022-05-25 2025-04-09 Celgene Corporation Methods of manufacturing t cell therapies
EP4615960A1 (en) 2022-11-09 2025-09-17 C3S2 GmbH Methods for manufacturing engineered immune cells
CN121100267A (zh) 2022-12-09 2025-12-09 朱诺治疗学股份有限公司 使用全息成像预测细胞表型的机器学习方法
CN121002052A (zh) 2023-02-03 2025-11-21 C3S2 有限公司 用于非病毒生产工程化免疫细胞的方法
KR20260005874A (ko) 2023-02-28 2026-01-12 주노 쎄러퓨티크스 인코퍼레이티드 전신 자가면역 질환을 치료하기 위한 세포 요법
WO2025049247A1 (en) 2023-08-25 2025-03-06 Juno Therapeutics, Inc. 5,6-core silacycle based inhibitors of dna-dependent protein kinase and compositions and application in gene editing
WO2025049253A1 (en) 2023-08-25 2025-03-06 Juno Therapeutics, Inc. Bridged cycle‑based inhibitors of dna‑dependent protein kinase and compositions and application in gene editing
WO2025049254A1 (en) 2023-08-25 2025-03-06 Juno Therapeutics, Inc. Pyrazolopyridine based inhibitors of dna-dependent protein kinase and compositions and application in gene editing
WO2025049250A1 (en) 2023-08-25 2025-03-06 Juno Therapeutics, Inc. 6,6-core silacycle based inhibitors of dna-dependent protein kinase and compositions and application in gene editing
AU2024364039A1 (en) 2023-10-18 2026-04-16 Tq Therapeutics Gmbh A method of manufacturing a cellular therapy product and respective kits and devices
US20250241912A1 (en) 2024-01-25 2025-07-31 Juno Therapeutics, Inc. Use of bridged cycle-based inhibitors of dna-dependent protein kinase in combination of dna polymerase theta inhibitor and compositions and application in gene editing
WO2025179188A1 (en) 2024-02-22 2025-08-28 Juno Therapeutics, Inc. Pyrazole-based inhibitors of dna-dependent protein kinase and compositions and applications in gene editing
EP4725578A1 (en) 2024-10-08 2026-04-15 TQ Therapeutics GmbH Column designs for affinity chromatography

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
DE4237113B4 (de) 1992-11-03 2006-10-12 "Iba Gmbh" Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
US5985658A (en) 1997-11-14 1999-11-16 Health Research Incorporated Calmodulin-based cell separation technique
EP1227321A1 (en) 2000-12-28 2002-07-31 Institut für Bioanalytik GmbH Reversible MHC multimer staining for functional purification of antigen-specific T cells
DE10113776B4 (de) 2001-03-21 2012-08-09 "Iba Gmbh" Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins
IL160358A0 (en) * 2001-08-23 2004-07-25 Genmab As Human antibodies specific for interleukin 15 (il-15)
FR2841905B1 (fr) 2002-07-05 2004-09-03 Centre Nat Rech Scient Fragments fab mutants de l'anticorps anti-cd4 chimere 13b8.2 et leurs applications
JP4517081B2 (ja) * 2005-12-22 2010-08-04 独立行政法人産業技術総合研究所 免疫センサ用デバイス
EP2093287A4 (en) * 2006-11-02 2010-04-21 Univ Kagoshima PEPTIDE BINDER IGG
CN101587043B (zh) * 2008-05-20 2013-10-02 北京莱尔生物医药科技有限公司 从生物体液样本中富集与检测稀有细胞的整合方法
US9273136B2 (en) 2008-08-04 2016-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human anti-human NKG2D monoclonal antibodies
TR201811128T4 (tr) * 2011-07-18 2018-08-27 Iba Gmbh Bir hedef hücrenin tersinir şekilde boyama yöntemi.

Also Published As

Publication number Publication date
JP2018119982A (ja) 2018-08-02
TR201811128T4 (tr) 2018-08-27
ES2682750T5 (en) 2025-02-04
CN107843730A (zh) 2018-03-27
PL2734538T5 (pl) 2025-11-12
EP2734538A2 (en) 2014-05-28
EP2734538B2 (en) 2024-07-03
EP3418295B1 (en) 2020-09-02
JP6310388B2 (ja) 2018-04-11
WO2013011011A2 (en) 2013-01-24
SI2734538T1 (sl) 2018-09-28
US20140295458A1 (en) 2014-10-02
ES2682750T3 (es) 2018-09-21
US20150301046A1 (en) 2015-10-22
US9023604B2 (en) 2015-05-05
JP6770989B2 (ja) 2020-10-21
CN107843730B (zh) 2021-08-20
EP3418295A1 (en) 2018-12-26
HK1258907A1 (en) 2019-11-22
EP2734538B1 (en) 2018-05-02
CN103797028B (zh) 2017-08-25
US9188589B2 (en) 2015-11-17
CN103797028A (zh) 2014-05-14
WO2013011011A3 (en) 2013-05-02
SI2734538T2 (sl) 2024-10-30
PT2734538T (pt) 2018-08-02
JP2014529361A (ja) 2014-11-06

Similar Documents

Publication Publication Date Title
PL2734538T3 (pl) Sposób odwracalnego barwienia komórki docelowej
IL288241A (en) Improved methods of cell culture for adoptive cell therapy
IL271005A (en) Improved methods of cell culture for adoptive cell therapy
CL2016001190A1 (es) Cultivo de células de mamífero.
PL3415616T3 (pl) Sposób odmładzania komórek
EP2788470A4 (en) CLOSED BIOREACTORS
EP2681306A4 (en) CELL CULTURE SYSTEM
PL2884999T3 (pl) Sposób i kompozycje do immunoterapii komórkowej
DK2900806T3 (da) Tredimensionel celledyrkning
HUE040455T2 (hu) T-sejt aktiválás inhibitorai
EP2772523A4 (en) REVERSIBLE THERMOCHROME COMPOSITIONS
HUE037174T2 (hu) Tenyésztõ tápközeg õssejtekhez
DK3351620T3 (da) Metabolsk optimeret cellekultur
DK3401319T3 (da) Celledyrkningsmedium
DK2780526T4 (da) Servo door closer
DK3395357T3 (da) Sammensætning til kontrolleret ovariestimulering
EP3719852C0 (en) SOLAR CELL
DK3144319T3 (da) Cellekultursammensætning indeholdende laminin-521
EP2914731A4 (en) REVERSIBLE GENE EXPRESSION
EP3066193C0 (en) CELL CULTURE PROCESS
EP2693624A4 (en) POWER CONTROL UNIT
EP2693625A4 (en) POWER CONTROL UNIT
FI20116329L (fi) Mittauskohteen mittaus
BR112013016341A2 (pt) método de congelamento de células
DK2681530T3 (da) Gennemstrømmelig målecelle